There has been a significant decline in small and mid-cap biotech stocks during the last month and a lot of names including Clovis Oncology (Nasdaq:CLVS) have seen a significant decline in value. It's not easy to see an investment decline
Clovis: Compelling With Upcoming Catalysts
Summary
- After a 25% selloff in the last 6 weeks, Clovis presents a compelling risk/reward ratio with upcoming catalysts in the next 3 months.
- Athena data is due in September which could move Rubraca into the largest oncology market in its class and make it a potential blockbuster.
- Targeted radiotherapy is the future of cancer treatment and Clovis is a pioneer in this area with its FAP pipeline.
- Earnings on August 4 will provide much-needed clarity from management.
I have been on the markets since 2006. I concentrate mostly on medium-term option trades. Among my big wins were betting against the oil spike in 2008, buying Green Mountain Coffee at $17, First solar at $14, and betting against Exxon Mobile before its collapse. My biggest failures have been investing in Fremont in 2008 and Synergy Pharmaceuticals in 2018 (both companies ended bankrupt.) Diversification is your biggest key to success in the markets. Even great losses won't make you loss your capital for reinvestment.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CLVS, BHC, CRWD, FLXN, UPST, VIAC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.